You are here

Share:

Peptide Inhibitors for Viral Infections and as Anti-inflammatory Agents

Summary
IFN-gamma and IL-10 are cytokine signaling molecules that play fundamental roles in inflammation, cancer growth and autoimmune diseases.  Unfortunately, there are no specific inhibitors of IFN-gamma or IL-10 on the market to date. The National Cancer Institute seeks parties interested in licensing or collaborative research to co-develop selective IL-10 and IFN-gamma peptide inhibitors.
NIH Reference Number
E-167-2010
Product Type
Keywords
  • Peptide
  • Peptidometic
  • Synthetic Peptide Inhibitors
  • Psoriasis
  • Interferon Gamma
  • IFN-gamma
  • Interleukin
Collaboration Opportunity
This invention is available for licensing and co-development.
Contact
Description of Technology

IFN-gamma and IL-10 are cytokine signaling molecules that play fundamental roles in inflammation, cancer growth and autoimmune diseases.  Unfortunately, there are no specific inhibitors of IFN-gamma or IL-10 on the market to date.

NCI investigators at the Cancer and Inflammation Program have synthesized short peptides that selectively interfere with dimerization of the cytokines and their binding to the corresponding receptor. The peptides include metabolically stable lipopeptides mimicking conserved regions of IL-10 and IFN-gamma receptors that interfere with STAT3 and STAT1 phosphorylation and subsequent signaling. The lipopeptides strongly inhibit STAT3 and STAT1-dependent growth of cancer cells. These compounds are promising drug candidates for the treatment of cancer and many infectious and inflammatory diseases. 

Potential Commercial Applications

- Cancer, viral infections and anti-inflammatory treatments
- Dermatological treatment for psoriasis

Competitive Advantages

- Rationally designed and synthesized to be potent, metabolically stable, and more therapeutic
- Highly selective IL-10 and IFN-gamma inhibitors

Inventor(s)

Nadya Tarasova (NCI), Giorgio Trinchieri (NCI), Howard Young (NCI)

Development Stage
Publications

Timofeeva OA, et al. [PMID: 18154267]

Patent Status
  • U.S. Patent Filed: U.S. Patent Application Number 13/697,259, Filed 19 Dec 2012
  • Foreign Filed: EP Application No. - Patent Application 11720697.9, Filed 11 May 2010
Therapeutic Area
Updated
Wednesday, August 31, 2016